P&R brief France: Recent developments in pharma pricing and market access

Published on February 4, 2024

Explore the key implications of the 2024 LFSS and CEPS report on the French pharmaceutical pricing and market access environment. Discover what it means for the industry. 

Both the 2024 LFSS (annual Social Security Financing Law) and the belated CEPS annual activity report for 2022 were published in January 2024, providing insights into the changing French P&MA environment.  

Here are the key implications from both reports on the French P&MA market.

How does the 2024 LFSS impact pricing and market access for drugs?  

Increased target for healthcare expenditures
  • The annual healthcare spending target (ONDAM) has increased to 254.9 billion euros, representing a growth of 3.2 percent compared to…

    Latest LFSS and CEPS report

Continue reading on website
Other news

True Profit! No Company Ever Went Broke Turning a Profit

February 1, 2024
Real profit after taxes is the most important management target. Profits are the cost of survival and the creators of new value. In this book, celebrated management thinker Hermann Simon brings clarity to the jungle of profit concepts and balance sheets. He sheds light on the performance of numerous companies and industries in international comparison and looks at the key profit drivers: price, sa

Growth Hacking: Testing fast and iterating to reach Digital Excellence

February 4, 2024
Is your financial institution facing increased competition from digital pure players, who usually display very low fees, propose state-of-the-art digital customer experience, and capture increasingly large share of new customers, especially the younger generation – a strategic target for most banks?Did you invest massively in IT & digital capabilities over the past decade, and need to monetize tho